delNS/E6E7
HPV-Induced Cervical Lesions (<CIN3)
Key Facts
About BlueSky Immunotherapies
BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.
View full company profileAbout BlueSky Immunotherapies
BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.
View full company profileAbout BlueSky Immunotherapies
BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.
View full company profileAbout BlueSky Immunotherapies
BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.
View full company profile